Tango Therapeutics, Inc. (NASDAQ:TNGX) Insider Sells $456,600.00 in Stock

Tango Therapeutics, Inc. (NASDAQ:TNGX) insider Mva Investors, Llc sold 60,000 shares of the company’s stock in a transaction dated Friday, May 3rd. The stock was sold at an average price of $7.61, for a total transaction of $456,600.00. Following the sale, the insider now directly owns 483,524 shares in the company, valued at $3,679,617.64. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Mva Investors, Llc also recently made the following trade(s):

• On Wednesday, May 1st, Mva Investors, Llc sold 75,000 shares of Tango Therapeutics stock. The stock was sold at an average price of $7.43, for a total value of $557,250.00.

Tango Therapeutics Stock Up 0.3 %

TNGX stock opened at $7.61 on Friday. Tango Therapeutics, Inc. has a twelve month low of $2.47 and a twelve month high of $13.03. The company has a market cap of $812.29 million, a P/E ratio of -6.92 and a beta of 0.84. The business has a fifty day moving average of $8.58 and a 200-day moving average of $9.33.

Tango Therapeutics (NASDAQ:TNGX) last announced its quarterly earnings data on Monday, March 18th. The company reported ($0.32) earnings per share for the quarter, missing the consensus estimate of ($0.28) by ($0.04). Tango Therapeutics had a negative return on equity of 41.96% and a negative net margin of 278.55%. The firm had revenue of $5.43 million for the quarter, compared to the consensus estimate of $7.86 million. As a group, equities research analysts anticipate that Tango Therapeutics, Inc. will post -1.28 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities analysts have issued reports on TNGX shares. HC Wainwright lifted their price objective on Tango Therapeutics from $16.00 to $17.00 and gave the company a “buy” rating in a research report on Wednesday, March 20th. Wedbush restated an “outperform” rating and issued a $18.00 target price on shares of Tango Therapeutics in a research note on Monday, March 18th. Cantor Fitzgerald initiated coverage on shares of Tango Therapeutics in a research report on Thursday, April 4th. They set an “overweight” rating on the stock. Finally, Piper Sandler assumed coverage on shares of Tango Therapeutics in a research note on Monday, February 12th. They issued an “overweight” rating and a $18.00 target price for the company. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company presently has an average rating of “Buy” and an average price target of $17.25.

Hedge Funds Weigh In On Tango Therapeutics

Several large investors have recently bought and sold shares of the business. Mirae Asset Global Investments Co. Ltd. grew its holdings in Tango Therapeutics by 32.6% during the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 28,964 shares of the company’s stock worth $230,000 after acquiring an additional 7,128 shares during the period. China Universal Asset Management Co. Ltd. increased its holdings in Tango Therapeutics by 65.9% in the first quarter. China Universal Asset Management Co. Ltd. now owns 19,569 shares of the company’s stock valued at $155,000 after purchasing an additional 7,776 shares during the last quarter. Simplicity Wealth LLC acquired a new position in Tango Therapeutics in the first quarter valued at about $214,000. Fishman Jay A Ltd. MI boosted its holdings in Tango Therapeutics by 71.4% during the first quarter. Fishman Jay A Ltd. MI now owns 24,000 shares of the company’s stock worth $191,000 after buying an additional 10,000 shares during the last quarter. Finally, Mass General Brigham Inc acquired a new position in shares of Tango Therapeutics during the 1st quarter worth about $2,812,000. 78.99% of the stock is currently owned by institutional investors and hedge funds.

About Tango Therapeutics

Tango Therapeutics, Inc, a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions.